Daiwa Securities Group’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-331
| Closed | -$1K | – | 1328 |
|
|
2024
Q4 | $1K | Hold |
331
| – | – | ﹤0.01% | 1278 |
|
|
2024
Q3 | $2K | Hold |
331
| – | – | ﹤0.01% | 1239 |
|
|
2024
Q2 | $1K | Hold |
331
| – | – | ﹤0.01% | 1312 |
|
|
2024
Q1 | $2K | Hold |
331
| – | – | ﹤0.01% | 1283 |
|
|
2023
Q4 | $3K | Hold |
331
| – | – | ﹤0.01% | 1259 |
|
|
2023
Q3 | $4K | Hold |
331
| – | – | ﹤0.01% | 1185 |
|
|
2023
Q2 | $8K | Hold |
331
| – | – | ﹤0.01% | 1151 |
|
|
2023
Q1 | $11K | Hold |
331
| – | – | ﹤0.01% | 1108 |
|
|
2022
Q4 | $6K | Buy |
331
+85
| +35% | +$1.94K | ﹤0.01% | 1150 |
|
|
2022
Q3 | $7K | Hold |
246
| – | – | ﹤0.01% | 1150 |
|
|
2022
Q2 | $3K | Hold |
246
| – | – | ﹤0.01% | 1212 |
|
|
2022
Q1 | $5K | Hold |
246
| – | – | ﹤0.01% | 1181 |
|
|
2021
Q4 | $4K | Hold |
246
| – | – | ﹤0.01% | 1232 |
|
|
2021
Q3 | $7K | Buy |
246
+105
| +74% | +$3K | ﹤0.01% | 1162 |
|
|
2021
Q2 | $4K | Hold |
141
| – | – | ﹤0.01% | 1097 |
|
|
2021
Q1 | $4K | Buy |
141
+16
| +13% | +$443 | ﹤0.01% | 1094 |
|
|
2020
Q4 | $4K | Sell |
125
-192
| -61% | -$4.97K | ﹤0.01% | 1076 |
|
|
2020
Q3 | $8K | Hold |
317
| – | – | ﹤0.01% | 1061 |
|
|
2020
Q2 | $5K | Hold |
317
| – | – | ﹤0.01% | 1109 |
|
|
2020
Q1 | $5K | Buy |
317
+37
| +13% | +$765 | ﹤0.01% | 1104 |
|
|
2019
Q4 | $5K | Hold |
280
| – | – | ﹤0.01% | 1110 |
|
|
2019
Q3 | $4K | Hold |
280
| – | – | ﹤0.01% | 1097 |
|
|
2019
Q2 | $4K | Hold |
280
| – | – | ﹤0.01% | 1121 |
|
|
2019
Q1 | $4K | Buy |
280
+78
| +39% | +$1.35K | ﹤0.01% | 1097 |
|
|
2018
Q4 | $4K | Hold |
202
| – | – | ﹤0.01% | 1077 |
|
|
2018
Q3 | $5K | Hold |
202
| – | – | ﹤0.01% | 1084 |
|
|
2018
Q2 | $6K | Hold |
202
| – | – | ﹤0.01% | 1088 |
|
|
2018
Q1 | $6K | Buy |
+202
| New | +$6.5K | ﹤0.01% | 1066 |
|
Other funds holding RVNC
Daiwa Securities Group's RVNC Position: Q1 2025 in Review
Daiwa Securities Group sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 331 shares — an estimated $1K sold.
Daiwa Securities Group first reported a position in RVNC in Q1 2018 and held it in 28 quarters. The position peaked at $11K in Q1 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- Daiwa Securities Group reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- Daiwa Securities Group sold 331 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $1K.
- Daiwa Securities Group first reported a position in Revance Therapeutics, Inc. in Q1 2018 and held it in 28 quarters.
- Daiwa Securities Group's Revance Therapeutics, Inc. position peaked at $11K in Q1 2023.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on Daiwa Securities Group's 13F filing for Q1 2025, filed 13 May 2025.